Efficacy and Safety of Seladelpar vs Placebo in Patients With Primary Biliary Cholangitis and Metabolic Syndrome in the Pivotal Phase 3 RESPONSE Study

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
Barcelona, Spain
May 27-30, 2026


Efficacy and Safety of Seladelpar vs Placebo in Patients With Primary Biliary Cholangitis and Metabolic Syndrome in the Pivotal Phase 3 RESPONSE Study

	EASL 2026 May 26-30 Barcelona Marlyn J. Mayo1,